Legal & General Group Plc Purchases 138,654 Shares of Zoetis Inc. $ZTS

Legal & General Group Plc raised its position in shares of Zoetis Inc. (NYSE:ZTS) by 4.1% in the fourth quarter, HoldingsChannel reports. The fund owned 3,554,498 shares of the company’s stock after acquiring an additional 138,654 shares during the period. Legal & General Group Plc’s holdings in Zoetis were worth $447,227,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently made changes to their positions in ZTS. Morningstar Investment Management LLC acquired a new stake in shares of Zoetis in the fourth quarter valued at approximately $6,264,000. Glenview Trust Co raised its position in shares of Zoetis by 13.6% in the fourth quarter. Glenview Trust Co now owns 5,849 shares of the company’s stock valued at $736,000 after buying an additional 702 shares in the last quarter. New Age Alpha Advisors LLC raised its position in shares of Zoetis by 6.8% in the fourth quarter. New Age Alpha Advisors LLC now owns 48,627 shares of the company’s stock valued at $6,118,000 after buying an additional 3,107 shares in the last quarter. Allen Capital Group LLC raised its position in shares of Zoetis by 35.0% in the fourth quarter. Allen Capital Group LLC now owns 38,177 shares of the company’s stock valued at $4,803,000 after buying an additional 9,904 shares in the last quarter. Finally, Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new stake in shares of Zoetis in the fourth quarter valued at approximately $719,000. Institutional investors own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

ZTS has been the subject of a number of analyst reports. BTIG Research reiterated a “buy” rating and issued a $160.00 price target on shares of Zoetis in a research report on Thursday, February 26th. William Blair reiterated an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. UBS Group dropped their price target on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research report on Friday, May 8th. Leerink Partners restated a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Finally, Bank of America boosted their price objective on shares of Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research report on Friday, February 13th. Seven equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $133.92.

Zoetis Stock Down 0.1%

Shares of ZTS opened at $81.26 on Tuesday. Zoetis Inc. has a one year low of $72.38 and a one year high of $172.23. The company has a market cap of $34.06 billion, a P/E ratio of 13.48, a P/E/G ratio of 1.33 and a beta of 0.87. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. The firm has a 50 day simple moving average of $107.43 and a two-hundred day simple moving average of $118.17.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The firm had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. During the same quarter in the prior year, the firm earned $1.48 earnings per share. The firm’s revenue for the quarter was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Research analysts forecast that Zoetis Inc. will post 6.88 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a dividend of $0.53 per share. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.6%. Zoetis’s dividend payout ratio is 35.16%.

Insider Transactions at Zoetis

In related news, Director Paul Bisaro purchased 2,000 shares of the stock in a transaction dated Wednesday, May 13th. The stock was bought at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the acquisition, the director owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. This represents a 7.73% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael B. Mccallister purchased 3,000 shares of the stock in a transaction dated Monday, May 11th. The shares were bought at an average price of $77.76 per share, with a total value of $233,280.00. Following the completion of the acquisition, the director directly owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. This represents a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders purchased 11,650 shares of company stock worth $886,384. Corporate insiders own 0.22% of the company’s stock.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.